159 related articles for article (PubMed ID: 18337114)
1. Clinical implications of BRAF mutation in thyroid carcinoma.
Puxeddu E; Durante C; Avenia N; Filetti S; Russo D
Trends Endocrinol Metab; 2008; 19(4):138-45. PubMed ID: 18337114
[TBL] [Abstract][Full Text] [Related]
2. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.
Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y
J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutations in papillary thyroid carcinoma.
Wojciechowska K; Lewinski A
Endocr Regul; 2006 Dec; 40(4):129-38. PubMed ID: 17201587
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Xing M
Endocr Rev; 2007 Dec; 28(7):742-62. PubMed ID: 17940185
[TBL] [Abstract][Full Text] [Related]
5. [BRAF gene mutation in thyroid cancer].
Kopczyńska E; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2006 Feb; 20(116):210-3. PubMed ID: 16708643
[TBL] [Abstract][Full Text] [Related]
6. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas.
Trovisco V; Soares P; Sobrinho-Simões M
Hum Pathol; 2006 Jul; 37(7):781-6. PubMed ID: 16784975
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutations in papillary carcinomas of the thyroid.
Fukushima T; Suzuki S; Mashiko M; Ohtake T; Endo Y; Takebayashi Y; Sekikawa K; Hagiwara K; Takenoshita S
Oncogene; 2003 Sep; 22(41):6455-7. PubMed ID: 14508525
[TBL] [Abstract][Full Text] [Related]
8. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
9. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose.
Takahashi K; Eguchi H; Arihiro K; Ito R; Koyama K; Soda M; Cologne J; Hayashi Y; Nakata Y; Nakachi K; Hamatani K
Mol Carcinog; 2007 Mar; 46(3):242-8. PubMed ID: 17186541
[TBL] [Abstract][Full Text] [Related]
10. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
11. Role of BRAF in thyroid oncogenesis.
Caronia LM; Phay JE; Shah MH
Clin Cancer Res; 2011 Dec; 17(24):7511-7. PubMed ID: 21900390
[TBL] [Abstract][Full Text] [Related]
12. BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
[TBL] [Abstract][Full Text] [Related]
13. [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice].
Zafon C; Obiols G
Endocrinol Nutr; 2009 Apr; 56(4):176-86. PubMed ID: 19627734
[TBL] [Abstract][Full Text] [Related]
14. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
15. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
[TBL] [Abstract][Full Text] [Related]
16. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions.
Handkiewicz-Junak D; Czarniecka A; Jarzab B
Mol Cell Endocrinol; 2010 Jun; 322(1-2):8-28. PubMed ID: 20138116
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
18. [BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].
Lopes JP; Fonseca E
Acta Med Port; 2011 Dec; 24 Suppl 4():855-68. PubMed ID: 22863493
[TBL] [Abstract][Full Text] [Related]
19. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Kondo T; Nakazawa T; Murata S; Kurebayashi J; Ezzat S; Asa SL; Katoh R
Hum Pathol; 2007 Dec; 38(12):1810-8. PubMed ID: 17714762
[TBL] [Abstract][Full Text] [Related]
20. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
